Dr. Yihua Sun 孙艺华
Chief Physician, Associate Professor
Department of Thoracic Surgery, Fudan University Shanghai Cancer Center, Shanghai
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Diagnosis and minimally invasive surgery for lung cancer, especially small pulmonary nodules. Treatment includes postoperative adjuvant and targeted therapy. Also performs minimally invasive surgery for esophageal cancer.
Dr. Sun graduated from Shanghai Medical University in 1999 and has worked in thoracic surgery since. Dr. Sun earned a medical doctorate from Shanghai Jiao Tong University in 2009. Clinical focus is on diagnosis and minimally invasive surgery for lung and esophageal cancer, with over 500 surgeries performed annually.
Professional roles
- Youth Committee Member, Thoracic Surgeons Branch, Chinese Medical Doctor Association
- Member, Shanghai Thoracic Surgery Branch, Chinese Medical Association
- Leader, Surgical Group, Thoracic Tumor Professional Committee, Shanghai Anti-Cancer Association
Name order: in Chinese the family name comes first (Sun Yihua). Papers usually list the name as Yihua Sun or Sun Y.
Selected publications
174 papers on PubMed matched by name and affiliation; 21 as first or senior author since 2016. Most recent first- or senior-author papers:
- JCO Precis Oncol, 2026 (senior author): Developing a Metabolic-Associated Prognostic Index for Risk Stratification and Therapeutic Guidance in Stage I Lung Adenocarcinoma via Multiomics Analysis. PubMed 41771017
- Exp Hematol Oncol, 2026 (senior author): Tertiary lymphoid structures correlate with reduced recurrence risk and enhanced antitumor immunity in esophageal squamous cell carcinoma with pathologic non-complete response to neoadjuvant chemoimmunotherapy. PubMed 41736069
- Transl Lung Cancer Res, 2025 (senior author): Subtype-specific RNA sequencing using micro-dissection revealed extracellular matrix alterations as key factors in lung adenocarcinoma invasion. PubMed 41367576
- Adv Sci (Weinh), 2025 (senior author): LncRNA TMEM99 Complexes with IGF2BP2 to Inhibit Autophagy in Lung Adenocarcinoma. PubMed 40704413
- Int J Cancer, 2025 (senior author): Tislelizumab combined with nab-paclitaxel and cisplatin as the more effective chemoimmunotherapy strategy in the neoadjuvant treatment of locally advanced thoracic esophageal squamous cell carcinoma: A prospective, two-cohort, phase 2 trial. PubMed 39686540
- Cancer Lett, 2024 (senior author): The single cell immunogenomic landscape after neoadjuvant immunotherapy combined chemotherapy in esophageal squamous cell carcinoma. PubMed 38734159
- Clin Lung Cancer, 2023 (senior author): Lobe-Specific Lymph Node Dissection May be Feasible for Clinical N0 Solid-Predominant Part-Solid Lung Adenocarcinoma With Solid Component Diameter ≤ 2 cm. PubMed 37029008
- Cancer Med, 2023 (senior author): Individualized prediction of survival benefit from postoperative radiotherapy for patients with malignant pleural mesothelioma. PubMed 37076977
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion